Germline FH mutations presenting with pheochromocytoma

Graeme R. Clark, Marco Sciacovelli, Edoardo Gaude, Diana M. Walsh, Gail Kirby, Michael A. Simpson, Richard C. Trembath, Jonathon N. Berg, Emma R. Woodward, Esther Kinning, Patrick J. Morrison, Christian Frezza, Eamonn R. Maher (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    42 Citations (Scopus)

    Abstract

    CONTEXT: At least a third of the patients with pheochromocytoma (PCC) or paraganglioma (PGL) harbor an underlying germline mutation in a known PCC/PGL gene. Mutations in genes (SDHB, SDHD, SDHC, and SDHA) encoding a component of the tricarboxylic acid cycle, succinate dehydrogenase (SDH), are a major cause of inherited PCC and PGL. SDHB mutations are also, albeit less frequently, associated with inherited renal cell carcinoma. Inactivation of SDH and another tricarboxylic acid cycle component, fumarate hydratase (FH), have both been associated with abnormalities of cellular metabolism, responsible for the activation of hypoxic gene response pathways and epigenetic alterations (eg, DNA methylation). However, the clinical phenotype of germline mutations in SDHx genes and FH is usually distinct, with FH mutations classically associated with hereditary cutaneous and uterine leiomyomatosis and renal cell carcinoma, although recently an association with PCC/PGL has been reported.
    OBJECTIVE AND DESIGN:To identify potential novel PCC/PGL predisposition genes, we initially undertook exome resequencing studies in a case of childhood PCC, and subsequently FH mutation analysis in a further 71 patients with PCC, PGL, or head and neck PGL. RESULTS: After identifying a candidate FH missense mutation in the exome study, we then detected a further candidate missense mutation (p.Glu53Lys) by candidate gene sequencing. In vitro analyses demonstrated that both missense mutations (p.Cys434Tyr and p.Glu53Lys) were catalytically inactive. CONCLUSIONS: These findings 1) confirm that germline FH mutations may present, albeit rarely with PCC or PGL; and 2) extend the clinical phenotype associated with FH mutations to pediatric PCC.
    Original languageEnglish
    Pages (from-to)E2046-E2050
    Number of pages5
    JournalJournal of Clinical Endocrinology and Metabolism
    Volume99
    Issue number10
    Early online date8 Jul 2014
    DOIs
    Publication statusPublished - Oct 2014

    Fingerprint

    Fumarate Hydratase
    Pheochromocytoma
    Paraganglioma
    Genes
    Mutation
    Missense Mutation
    Succinate Dehydrogenase
    Exome
    Citric Acid Cycle
    Germ-Line Mutation
    Renal Cell Carcinoma
    Cells
    Pediatrics
    Leiomyomatosis
    Phenotype
    Ports and harbors
    Metabolism
    DNA Methylation
    Epigenomics
    Chemical activation

    Cite this

    Clark, G. R., Sciacovelli, M., Gaude, E., Walsh, D. M., Kirby, G., Simpson, M. A., ... Maher, E. R. (2014). Germline FH mutations presenting with pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 99(10), E2046-E2050. https://doi.org/10.1210/jc.2014-1659
    Clark, Graeme R. ; Sciacovelli, Marco ; Gaude, Edoardo ; Walsh, Diana M. ; Kirby, Gail ; Simpson, Michael A. ; Trembath, Richard C. ; Berg, Jonathon N. ; Woodward, Emma R. ; Kinning, Esther ; Morrison, Patrick J. ; Frezza, Christian ; Maher, Eamonn R. . / Germline FH mutations presenting with pheochromocytoma. In: Journal of Clinical Endocrinology and Metabolism. 2014 ; Vol. 99, No. 10. pp. E2046-E2050.
    @article{9a01fd76b6a34e7ea3cae55fb739a03b,
    title = "Germline FH mutations presenting with pheochromocytoma",
    abstract = "CONTEXT: At least a third of the patients with pheochromocytoma (PCC) or paraganglioma (PGL) harbor an underlying germline mutation in a known PCC/PGL gene. Mutations in genes (SDHB, SDHD, SDHC, and SDHA) encoding a component of the tricarboxylic acid cycle, succinate dehydrogenase (SDH), are a major cause of inherited PCC and PGL. SDHB mutations are also, albeit less frequently, associated with inherited renal cell carcinoma. Inactivation of SDH and another tricarboxylic acid cycle component, fumarate hydratase (FH), have both been associated with abnormalities of cellular metabolism, responsible for the activation of hypoxic gene response pathways and epigenetic alterations (eg, DNA methylation). However, the clinical phenotype of germline mutations in SDHx genes and FH is usually distinct, with FH mutations classically associated with hereditary cutaneous and uterine leiomyomatosis and renal cell carcinoma, although recently an association with PCC/PGL has been reported.OBJECTIVE AND DESIGN:To identify potential novel PCC/PGL predisposition genes, we initially undertook exome resequencing studies in a case of childhood PCC, and subsequently FH mutation analysis in a further 71 patients with PCC, PGL, or head and neck PGL. RESULTS: After identifying a candidate FH missense mutation in the exome study, we then detected a further candidate missense mutation (p.Glu53Lys) by candidate gene sequencing. In vitro analyses demonstrated that both missense mutations (p.Cys434Tyr and p.Glu53Lys) were catalytically inactive. CONCLUSIONS: These findings 1) confirm that germline FH mutations may present, albeit rarely with PCC or PGL; and 2) extend the clinical phenotype associated with FH mutations to pediatric PCC.",
    author = "Clark, {Graeme R.} and Marco Sciacovelli and Edoardo Gaude and Walsh, {Diana M.} and Gail Kirby and Simpson, {Michael A.} and Trembath, {Richard C.} and Berg, {Jonathon N.} and Woodward, {Emma R.} and Esther Kinning and Morrison, {Patrick J.} and Christian Frezza and Maher, {Eamonn R.}",
    year = "2014",
    month = "10",
    doi = "10.1210/jc.2014-1659",
    language = "English",
    volume = "99",
    pages = "E2046--E2050",
    journal = "Journal of Clinical Endocrinology and Metabolism",
    issn = "0021-972X",
    publisher = "Endocrine Society",
    number = "10",

    }

    Clark, GR, Sciacovelli, M, Gaude, E, Walsh, DM, Kirby, G, Simpson, MA, Trembath, RC, Berg, JN, Woodward, ER, Kinning, E, Morrison, PJ, Frezza, C & Maher, ER 2014, 'Germline FH mutations presenting with pheochromocytoma', Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 10, pp. E2046-E2050. https://doi.org/10.1210/jc.2014-1659

    Germline FH mutations presenting with pheochromocytoma. / Clark, Graeme R.; Sciacovelli, Marco; Gaude, Edoardo; Walsh, Diana M.; Kirby, Gail ; Simpson, Michael A.; Trembath, Richard C.; Berg, Jonathon N.; Woodward, Emma R.; Kinning, Esther; Morrison, Patrick J.; Frezza, Christian; Maher, Eamonn R. (Lead / Corresponding author).

    In: Journal of Clinical Endocrinology and Metabolism, Vol. 99, No. 10, 10.2014, p. E2046-E2050.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Germline FH mutations presenting with pheochromocytoma

    AU - Clark, Graeme R.

    AU - Sciacovelli, Marco

    AU - Gaude, Edoardo

    AU - Walsh, Diana M.

    AU - Kirby, Gail

    AU - Simpson, Michael A.

    AU - Trembath, Richard C.

    AU - Berg, Jonathon N.

    AU - Woodward, Emma R.

    AU - Kinning, Esther

    AU - Morrison, Patrick J.

    AU - Frezza, Christian

    AU - Maher, Eamonn R.

    PY - 2014/10

    Y1 - 2014/10

    N2 - CONTEXT: At least a third of the patients with pheochromocytoma (PCC) or paraganglioma (PGL) harbor an underlying germline mutation in a known PCC/PGL gene. Mutations in genes (SDHB, SDHD, SDHC, and SDHA) encoding a component of the tricarboxylic acid cycle, succinate dehydrogenase (SDH), are a major cause of inherited PCC and PGL. SDHB mutations are also, albeit less frequently, associated with inherited renal cell carcinoma. Inactivation of SDH and another tricarboxylic acid cycle component, fumarate hydratase (FH), have both been associated with abnormalities of cellular metabolism, responsible for the activation of hypoxic gene response pathways and epigenetic alterations (eg, DNA methylation). However, the clinical phenotype of germline mutations in SDHx genes and FH is usually distinct, with FH mutations classically associated with hereditary cutaneous and uterine leiomyomatosis and renal cell carcinoma, although recently an association with PCC/PGL has been reported.OBJECTIVE AND DESIGN:To identify potential novel PCC/PGL predisposition genes, we initially undertook exome resequencing studies in a case of childhood PCC, and subsequently FH mutation analysis in a further 71 patients with PCC, PGL, or head and neck PGL. RESULTS: After identifying a candidate FH missense mutation in the exome study, we then detected a further candidate missense mutation (p.Glu53Lys) by candidate gene sequencing. In vitro analyses demonstrated that both missense mutations (p.Cys434Tyr and p.Glu53Lys) were catalytically inactive. CONCLUSIONS: These findings 1) confirm that germline FH mutations may present, albeit rarely with PCC or PGL; and 2) extend the clinical phenotype associated with FH mutations to pediatric PCC.

    AB - CONTEXT: At least a third of the patients with pheochromocytoma (PCC) or paraganglioma (PGL) harbor an underlying germline mutation in a known PCC/PGL gene. Mutations in genes (SDHB, SDHD, SDHC, and SDHA) encoding a component of the tricarboxylic acid cycle, succinate dehydrogenase (SDH), are a major cause of inherited PCC and PGL. SDHB mutations are also, albeit less frequently, associated with inherited renal cell carcinoma. Inactivation of SDH and another tricarboxylic acid cycle component, fumarate hydratase (FH), have both been associated with abnormalities of cellular metabolism, responsible for the activation of hypoxic gene response pathways and epigenetic alterations (eg, DNA methylation). However, the clinical phenotype of germline mutations in SDHx genes and FH is usually distinct, with FH mutations classically associated with hereditary cutaneous and uterine leiomyomatosis and renal cell carcinoma, although recently an association with PCC/PGL has been reported.OBJECTIVE AND DESIGN:To identify potential novel PCC/PGL predisposition genes, we initially undertook exome resequencing studies in a case of childhood PCC, and subsequently FH mutation analysis in a further 71 patients with PCC, PGL, or head and neck PGL. RESULTS: After identifying a candidate FH missense mutation in the exome study, we then detected a further candidate missense mutation (p.Glu53Lys) by candidate gene sequencing. In vitro analyses demonstrated that both missense mutations (p.Cys434Tyr and p.Glu53Lys) were catalytically inactive. CONCLUSIONS: These findings 1) confirm that germline FH mutations may present, albeit rarely with PCC or PGL; and 2) extend the clinical phenotype associated with FH mutations to pediatric PCC.

    UR - http://www.scopus.com/inward/record.url?scp=84907653297&partnerID=8YFLogxK

    U2 - 10.1210/jc.2014-1659

    DO - 10.1210/jc.2014-1659

    M3 - Article

    VL - 99

    SP - E2046-E2050

    JO - Journal of Clinical Endocrinology and Metabolism

    JF - Journal of Clinical Endocrinology and Metabolism

    SN - 0021-972X

    IS - 10

    ER -

    Clark GR, Sciacovelli M, Gaude E, Walsh DM, Kirby G, Simpson MA et al. Germline FH mutations presenting with pheochromocytoma. Journal of Clinical Endocrinology and Metabolism. 2014 Oct;99(10):E2046-E2050. https://doi.org/10.1210/jc.2014-1659